DUBLIN, Ireland, August 01, 2022 (GLOBE NEWSWIRE) — Prothena Corporation plc PRTAa late-stage clinical biotechnology company with a solid pipeline of investigational therapeutics built on expertise in protein dysregulation, today announced that it released its financial results for the second quarter and first six months of 2022 on Monday, April 8 financial markets.

Consistent with past practice, the Company will not be conducting a conference call in connection with this August 8th financial results release.

About prothena

Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Driven by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates across a range of indications and novel targets for which its ability to advance scientific knowledge of neurological dysfunction and the biology of misfolded proteins to integrate, can be used. Prothena’s pipeline includes both proprietary and partnered programs being developed for potential treatments of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, visit the company’s website at www.prothena.com and follow the company on Twitter @ProthenaCorp.

Contacts:

investors
Jennifer Zibuda, Director, Investor Relations & Communications
650-837-8535, jennifer.zibuda@prothena.com

media
Eric Endicott, Senior Vice President, Corporate Affairs
650-448-3670, eric.endicott@prothena.com